Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Interest Expenses (2018 - 2025)

Historic Interest Expenses for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to $2.3 million.

  • X4 Pharmaceuticals' Interest Expenses fell 650.37% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year increase of 771.26%. This contributed to the annual value of $8.8 million for FY2024, which is 5177.43% up from last year.
  • According to the latest figures from Q3 2025, X4 Pharmaceuticals' Interest Expenses is $2.3 million, which was down 650.37% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, X4 Pharmaceuticals' Interest Expenses registered a high of $2.4 million during Q3 2024, and its lowest value of $891000.0 during Q1 2021.
  • Moreover, its 5-year median value for Interest Expenses was $1.1 million (2023), whereas its average is $1.5 million.
  • Its Interest Expenses has fluctuated over the past 5 years, first surged by 8954.7% in 2024, then plummeted by 650.37% in 2025.
  • Over the past 5 years, X4 Pharmaceuticals' Interest Expenses (Quarter) stood at $925000.0 in 2021, then increased by 23.68% to $1.1 million in 2022, then surged by 64.86% to $1.9 million in 2023, then grew by 22.16% to $2.3 million in 2024, then dropped by 2.04% to $2.3 million in 2025.
  • Its Interest Expenses was $2.3 million in Q3 2025, compared to $2.2 million in Q2 2025 and $2.2 million in Q1 2025.